Food and Drug Administration.Guidance for Industry: Establishing pregnancy exposure registries. Rockville (MD): US Department of Health and Human Services, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research; 2002. Available from URL: http://www.fda.gov/cber/gdlns/pregnancy.pdf.
Food and Drug Administration. Guidance for Industry. Good Pharmacovigilance Reporting and Pharmacoepidemiology Practices. US Dept of Health and Human Services, Food and Drug Administration, Rockville, Maryland. March 2005.
Scheurle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signaling in a pregnancy registry. Pharmacoepidemiology & Drug Safety. 2002; 11: 465-475.
International Conference on Harmonization. E6: Guideline for Good Clinical Practice, 1996. Accessed from http://www.ich.org/cache/compo/276-254-1.html on January 27, 2006.
Centers for Disease Control and Prevention: Metropolitan Atlanta Congenital Defects Program Procedure Manual. July 1989 (Revised January 1998); A1-B11. To obtain a copy of the MACDP Procedure Manual or Defect Code, send an email request to macdp@cdc.gov.
Correa A, Cragan J, Kucik J, et al.. Metropolitan Atlanta Congenital Defects Program 40th Anniversary Edition Surveillance Report: Reporting Birth Defects Surveillance Data 1968-2003. Birth Defects Research (Part A). 2007;79:65-93.
Yonkers KA; Wisner KL; Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009; 31(5): 403-13.